|Videos|October 10, 2017

What Advantage Does Delafoxacin Have Over Other Fluoroquinolones?

Author(s)Contagion&reg Editorial Staff

Sue Cammarata, MD, explains the advantages that delafloxcin has over other fluoroquinolones.

Sue Cammarata, MD, CMO of Melinta Therapeutics, explains the advantages that delafloxcin has over other available fluoroquinolones. When it comes to adverse events, other fluoroquinolones are known to cause heart arrhythmias, cause reactions in sunshine, as well as liver or sugar/glucose abnormalities, where delafloxcin does not.

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Latest CME

Virtual Event

Louisiana Oncology Society

2 Sessions are Available!

Virtual Event

Missouri Oncology Society

2 Sessions are Available!

Virtual Event

New Mexico Society of Clinical Oncology

2 Sessions are Available!

Virtual Event

Indiana Oncology Society

2 Sessions are Available!

Virtual Event

Arkansas Association of Cancer Professionals

1 Session is Available!

Virtual Event

Rhode Island Oncology Society

2 Sessions are Available!

Virtual Event

Kentucky Society of Clinical Oncology

2 Sessions are Available!

What Advantage Does Delafoxacin Have Over Other Fluoroquinolones?

Related Content

10 Infectious Disease Developments That Defined Q2 2026

Considering Diversified Treatment Strategies to Combat Gonorrhea Resistance

Efflux Pump Inhibitor Restores Azithromycin Activity Against Multidrug-Resistant Gram-Negative Pathogens

Review of Cefepime and Zidebactam: A Novel Antibiotic Approved to Treat Complicated Urinary Tract Infections

FDA Approves Tebipenem Pivoxil as First Oral Carbapenem for Complicated Urinary Tract Infections

Latest CME

Louisiana Oncology Society

Missouri Oncology Society

New Mexico Society of Clinical Oncology

Indiana Oncology Society

Arkansas Association of Cancer Professionals

Rhode Island Oncology Society

Kentucky Society of Clinical Oncology

PER Global Perspectives: Differentiating and Managing Toxicities with TROP2-Targeted ADCs in NSCLC Through Multidisciplinary Pathways

Interventional Dry Eye: A Stepwise Treatment & Management Approach

Empire State Hematology & Oncology Society (New York)

Minnesota Society of Clinical Oncology

North Carolina Oncology Association

Kansas Society of Clinical Oncology

Colorado Oncology Society

Wyoming State Oncology Society

Montana State Oncology Society

Arizona Clinical Oncology Society

Nevada Oncology Society

Radioligand Therapy 101: The Science Behind the Strategy

Tackling Barriers to Vaccine Uptake: Practical Strategies for Adult Immunization

Burst CME CGM: Continuous Glucose Monitoring Considerations – Maximizing Quality of Life for Patients

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

A Shield of Protection: Unmet Needs in COVID-19 Prevention and Control

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

MacTel Decoded: Rethinking Conventional Approaches With Novel Neuroprotective Strategies

(CME Track) Transforming DED Management in Breaking Thermal Barriers

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

ISGIO 2025: Pancreatic and Neuroendocrine Tumors

Community Practice Connections™ Next Generation Therapies in AML: Menin Inhibitors, IDH1/2, Combinations, and Beyond!

Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Diagnosis and Management of TGCT

Revolutionizing TGCT Care with Multidisciplinary Perspectives and Cutting-Edge Targeted Therapies

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Rhode Island

Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

10th Annual Live Medical Crossfire®: Hematologic Malignancies

Medical Crossfire®: DLL3-Driven Innovations in Small Cell Lung Cancer – How Do Experts Apply Pivotal Advances to Practice?

Southern California Psychiatry Conference

25th Annual International Congress on the Future of Breast Cancer® East

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Show Me the Data™ New Frontiers in the Treatment of Ovarian Cancer

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Oncology Town Hall: From Evidence to Action—Applying KRAS-Targeted Advances in Solid Tumors

Retina Updates in Montréal

A Community-Based Roadmap to CAR-T Therapy: Optimizing Delivery and Outcomes

Wisconsin Association of Hematology and Oncology

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

PER Global Perspectives: Preparing for the Emergence of TROP2 ADCs With Immunotherapy in the Earlier Treatment Settings

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Burst CME: Managing Fluid Overload in Patients with Chronic Kidney Disease (Part 1)

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Looking Beneath the Surface: Latest Updates in Identifying and Managing Hypercortisolism in Patients with Type 2 Diabetes

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Community Practice Connections™: 16th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™